Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands
Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.678
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2013
Authors
Publisher
Elsevier BV